Navigation Links
XTENT Announces Third Quarter 2007 Financial Results
Date:11/2/2007

MENLO PARK, Calif., Nov. 2 /PRNewswire-FirstCall/ -- XTENT, Inc. (Nasdaq: XTNT) today reported financial results for the third quarter ended September 30, 2007.

The company reported a net loss of $9.5 million, or $0.42 per share, for the third quarter of 2007, compared to a net loss of $8.0 million, or $2.84 per share, for the same period last year. The company's net loss per share for the third quarter of 2007 was based on weighted average shares outstanding of 22.7 million as compared to 2.8 million weighted average shares outstanding for the quarter ended September 30, 2006. For the nine months ended September 30, 2007, XTENT had a net loss of $26.9 million, compared to $17.9 million for the same period last year. The net loss attributable to common stockholders was $26.9 million for the nine months ended September 30, 2007, compared to $31.0 million for the same period last year. At September 30, 2007, XTENT had cash, cash equivalents and short-term investments of $68.1 million.

Research and development expenses increased to $7.8 million in the third quarter of 2007 from $5.8 million for the same period last year primarily due to an increased number of research and development personnel and expenditures for prototype parts, supplies, and outside services related to product development for our Custom NX DES systems. General and administrative expenses were unchanged at $2.6 million in the third quarter of 2007 versus $2.6 million for the same period last year. Research and development expenses for the nine month period ended September 30, 2007, totaled $21.7 million, compared to $13.4 million for the same period last year. General and administrative expenses for the nine months ended September 30, 2007, totaled $7.9 million, compared to $5.3 million for the same period in 2006.

"We continue to make excellent progress in the development of our innovative stent systems," commented Gregory D. Casciaro, XTENT's President and CEO. "In October, we announced very encouraging results from our CUSTOM I and CUSTOM II clinical trials at the Transcatheter Cardiovascular Therapeutics (TCT) conference. At two year follow-up for CUSTOM I and one year follow-up for CUSTOM II, no new major adverse cardiac (MACE) events were reported. In addition, the incidence of late stent thrombosis in both trials was zero. Everyone at XTENT continues to be very focused on the execution of clinical, regulatory and product development milestones."

Third Quarter 2007 Highlights:

-- Completion of patient enrollment in the 90-patient CUSTOM III clinical

trial

-- Appointment of Michael Eagle, former Vice President, Manufacturing, at

Eli Lilly and Company, to the Board of Directors

-- Filed an Investigational Device Exemption (IDE) application with the

United States Food and Drug Administration (FDA) to begin the CUSTOM IV

pivotal trial. As the company announced on October 22, 2007, at the

Transcatheter Cardiovascular Therapeutics meeting in Washington D.C.,

it recently received questions back from the FDA regarding the IDE

application, and it is working to address these questions which must be

resolved before the company can initiate its Custom IV pivotal trial.

Conference Call and Webcast Information

The company will not be hosting a quarterly earnings call for the third quarter of 2007 as it provided an update during its conference call and webcast at TCT on October 22, 2007.

About XTENT

XTENT, Inc. is a medical device company focused on developing and commercializing innovative customizable drug eluting stent (DES) systems for the treatment of coronary artery disease (CAD). CAD is the most common form of cardiovascular disease and the number one cause of death in the United States and Europe. XTENT(R) Custom NX(R) DES Systems are designed to enable the treatment of single lesions, long lesions and multiple lesions of varying lengths and diameters, in one or more arteries with a single device. Note: XTENT(R) Custom NX(R) DES Systems have not been approved for sale by any regulatory authority.

XTENT, INC.

(a development stage company)

Condensed Statements of Operations

(unaudited; in thousands, except per share amounts)

Three Months Ended Nine Months Ended

September 30, September 30,

2007 2006 2007 2006

Operating expenses:

Research and development (1) $7,767 $5,844 $21,694 $13,403

General and administrative (1) 2,632 2,594 7,894 5,277

Total operating expenses 10,399 8,438 29,588 18,680

Loss from operations (10,399) (8,438) (29,588) (18,680)

Interest and other income, net 860 396 2,658 801

Net loss (9,539) (8,042) (26,930) (17,879)

Deemed dividend related to

beneficial conversion feature

of redeemable convertible preferred

stock - - - (13,095)

Net loss attributable to common

stockholders $(9,539) $(8,042) $(26,930) $(30,974)

Net loss per share attributable to

common stockholders - basic and

diluted $(0.42) $(2.84) $(1.35) $(11.65)

Weighted-average common shares

outstanding used in per share

calculation 22,656 2,830 19,999 2,658

(1) Includes the following stock-based

compensation charges:

Research and development $294 $524 $1,030 $850

General and administrative $490 $362 $1,322 $578

XTENT, INC.

(a development stage company)

Condensed Balance Sheets

(unaudited, in thousands)

September 30, December 31,

2007 2006

Cash and cash equivalents and short term

investments $68,095 $23,105

Working capital 64,911 21,066

Total assets 72,338 27,121

Redeemable convertible preferred stock - 75,593

Deficit accumulated during the development

stage (80,996) (54,066)

Total stockholders' equity (deficit) 68,671 (50,780)


'/>"/>
SOURCE XTENT, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. New Findings Could Reduce The Extent Of Spinal Cord Injuries
2. Students wants to extent Tution waiver in Ontario
3. Extent of Brain Involvement at Diagnosis May Predict Brain Atrophy
4. WTC Neighborhood Residents Misled on Extent of Contamination
5. PM announces a new health care order for India
6. Ramdoss Announces Introduction of RCH-II
7. Britain Announces Third Transfusion Related Mad Cow Case
8. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
9. Tibet Announces the Dalai Lama’s Tour of South Americ
10. NHS announces further Cost cutting Measures
11. Indian PM Announces Of Setting Up India Study Center At Tashkent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... 2016 , ... Intermedix announced on Wednesday that it was ... medicine professional association, to support the organization's newly established physician group with a ... Medicine, or AAEM, seeks to empower emergency physicians to control their own practices. ...
(Date:2/10/2016)... Tarzana, CA (PRWEB) , ... February 10, 2016 ... ... Fernando Valley , announces that his office is now offering a variety of ... cheek enhancement, chin enhancement, eyebrow lift, facial volume restoration, lip enhancement and nasal ...
(Date:2/10/2016)... ... February 10, 2016 , ... Gout is like no other joint pain. ... often severe, with intense swelling and redness. It is triggered by the crystallization of ... adults are the most susceptible, according to the February 2016 issue of Harvard Men's ...
(Date:2/10/2016)... ... ... For additional information contact Phyllis Strupp 480-488-5858 , Brain improves with age, ... Guide to Brain Training" by award-winning author Phyllis Strupp explains how brain ... 16, 2016. A free review copy is available to the media at NetGalley ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... February 26th: Amateur & Professional Divisions - Time: 7:00pm – 10:00pm | ... | Ticket Prices $30, Social Media: http://www.USPoleSportsFed.org , Facebook: http://www.facebook.com/uspolesportsfederation ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... 2016 CSI Specialty Group (CSI) expanded its ... the Specialty Pharmacy Podcast. A free, weekly show, the ... real-world education, discussion and context amongst specialty pharmacy peers ... --> The Specialty Pharmacy Podcast, hosted by ... Group Suzette DiMascio, CHE, CMCE, CPC, is available for ...
(Date:2/10/2016)... , Feb. 10, 2016 Immune Pharmaceuticals Inc. ... announced today that it has filed a patent application ... other cancers. --> --> ... by administration of Ceplene (histamine dihydrochloride) in combination with ... of predicting the efficacy of Ceplene and IL-2 therapy ...
(Date:2/10/2016)...  The ALS Association, in partnership with ALS Finding a ... a biomarker to track TDP43 aggregation. The successful team(s) with ... million investment. --> --> ... cells in the brain and the spinal cord. Eventually, people ... movement, which often leads to total paralysis and death within ...
Breaking Medicine Technology: